In vitro analysis of stable, receptor-selective neurotensin[8-13] analogues

Journal of Medicinal Chemistry

Volumn 46, Issue 19, 2003, Pages 4141-4148

  Kokko, Kyle P ^a   Hadden, M Kyle ^a   Orwig, Kevin S ^a   Mazella, Jean ^b   Dix, Thomas A ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CNRS   (France)

^c Argolyn Biosciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; NEUROTENSIN DERIVATIVE; NEUROTENSIN RECEPTOR; PHOSPHATIDYLINOSITIDE; TYROSINE;

AMINO ACID SUBSTITUTION; AMINO ACID SYNTHESIS; ANIMAL CELL; ARTICLE; BINDING AFFINITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PROTEIN ANALYSIS; RAT; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; AMINO ACIDS; ANIMALS; COS CELLS; DRUG STABILITY; HALF-LIFE; HUMANS; NEUROTENSIN; PEPTIDE FRAGMENTS; PHOSPHATIDYLINOSITOLS; RATS; RECEPTORS, NEUROTENSIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRANSFECTION;

EID: 0141567435     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0300633     Document Type: Article

References (55)

1. Carraway, R.; Leeman, S. E. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem. 1973, 248, 6854-6861.
2. Bozou, J. C.; Amar, S.; Vincent, J. P.; Kitabgi, P. Neurotensin mediated inhibition of cyclic AMP formation in neuroblastoma N1E115 cells: involvement of the inhibitory GTP-binding component of adenylate cyclase. Mol. Pharmacol. 1986, 29, 489-496.
3. Gilbert, J. A.; Richelson, E. Neurotensin stimulates formation of cyclic GMP in murine neuroblastoma clone N1E-115. Eur. J. Pharmacol. 1984, 99, 245-246.
4. Snider, R. M.; Forray, C.; Pfenning, M.; Richelson, E. Neurotensin stimulates inositol phospholipid metabolism and calcium mobilization in murine neuroblastoma clone N1E-115. J. Neurochem. 1986, 47, 1214-1218.
5. Memo, M.; Castelletti, L.; Valerio, A.; Missale, C.; Spano, P. F. Identification of neurotensin receptors associated with calcium channels and prolactin release in rat pituitary. J. Neurochem. 1986, 47, 1682-1688.
6. Hermans, E.; Maloteaux, J. M.; Octave, J. N. Phospholipase C activation by neurotensin and neuromedin N in Chinese hamster ovary cells expressing the rat neurotensin receptor. Brain Res. Mol. Brain Res. 1992, 15, 332-338.
7. Lopez Ordieres, M. G.; Rodriquez de Lores Arnaiz, G. Neurotensin inhibits neuronal Na+, K+-ATPase activity through high affinity peptide receptor. Peptides 2000, 21, 571-576.
8. Osbahr, A. J., III; Nemeroff, C. B.; Manberg, P. J.; Prange, A. J., Jr. Centrally administered neurotensin: activity in the Julou-Courvoisier muscle relaxation test in mice. Eur. J. Pharmacol. 1979, 54, 299-302.
9. Luttinger, D.; King, R. A.; Sheppard, D.; Strupp, J.; Nemeroff, C. B. et al. The effect of neurotensin on food consumption in the rat. Eur. J. Pharmacol. 1982, 81, 499-503.
10. Snijders, R.; Kramarcy, N. R.; Hurd, R. W.; Nemeroff, C. B.; Dunn, A. J. Neurotensin induces catalepsy in mice. Neuropharmacology 1982, 21, 465-468.
11. Dubuc, I.; Costentin, J.; Terranova, J. P.; Barnouin, M. C.; Soubrie, P. et al. The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes. Br. J. Pharmacol. 1994, 112, 352-354.
12. Bissette, G.; Nemeroff, C. B.; Loosen, P. T.; Prange, A. J., Jr.; Lipton, M. A. Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. Nature 1976, 262, 607-609.
13. Nemeroff, C. B.; Osbahr, A. J., 3rd; Manberg, P. J.; Ervin, G. N.; Prange, A. J., Jr. Alterations in nociception and body temperature after intracisternal administration of neurotensin, beta-endorphin, other endogenous peptides, and morphine. Proc. Natl. Acad. Sci. U. S. A. 1979, 76, 5368-5371.
14. Kinkead, B.; Nemeroff, C. B. The effects of typical and atypical antipsychotic drugs on neurotensin-containing neurons in the central nervous system. J. Clin. Psychiatry 1994, 55 Suppl B, 30-32.
15. Feifel, D.; Reza, T. L.; Robeck, S. L. Pro-dopamine effects of neurotensin on sensorimotor gating deficits. Peptides 1997, 18, 1457-1460.
16. Ervin, G. N.; Birkemo, L. S.; Nemeroff, C. B.; Prange, A. J., Jr. Neurotensin blocks certain amphetamine-induced behaviours. Nature 1981, 291, 73-76.
17. Nemeroff, C. B.; Bissette, G.; Prange, A. J., Jr.; Loosen, P. T.; Barlow, T. S. et al. Neurotensin: central nervous system effects of a hypothalamic peptide. Brain Res. 1977, 128, 485-496.
18. Vincent, J. P.; Mazella, J.; Kitabgi, P. Neurotensin and neurotensin receptors. Trends Pharmacol, Sci. 1999, 20, 302-309.
19. Mazella, J.; Zsurger, N.; Navarro, V.; Chabry, J.; Kaghad, M. et al. The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J. Biol. Chem. 1998, 273, 26273-26276.
20. Gully, D.; Canton, M.; Boigegrain, R.; Jeanjean, F.; Molimard, J. C. et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 65-69.
21. Gully, D.; Labeeuw, B.; Boigegrain, R.; Oury-Donat, F.; Bachy, A. et al. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J. Pharmacol. Exp. Ther. 1997, 280, 802-812.
22. Pettibone, D. J.; Hess, J. F.; Hey, P. J.; Jacobson, M. A.; Leviten, M. et al. The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin. J. Pharmacol. Exp. Ther. 2002, 300, 305-313.
23. Dubuc, I.; Sarret, P.; Labbe-Jullie, C.; Botto, J. M.; Honore, E. et al. Identification of the receptor subtype involved in the analgesic effect of neurotensin. J. Neurosci. 1999, 19, 503-510.
24. Tyler, B. M.; Cusack, B.; Douglas, C. L.; Souder, T.; Richelson, E. Evidence for additional neurotensin receptor subtypes: neurotensin analogues that distinguish between neurotensin-mediated hypothermia and antinociception. Brain Res. 1998, 792, 246-252.
25. Carraway, R.; Leeman, S. E. Structural Requirements for the Biological Activity of Neurotensin, a New Vasoactive Peptide. Peptides: Chemistry, Structure and Biology; Ann Arbor Science: Ann Arbor, 1975; pp 679-685.
26. Banks, W. A.; Wustrow, D. J.; Cody, W. L.; Davis, M. D.; Kastin, A. J. Permeability of the blood-brain barrier to the neurotensin8-13 analogue NT1. Brain Res. 1995, 695, 59-63.
27. Cusack, B.; Chou, T.; Jansen, K.; McCormick, D. J.; Richelson, E. Analysis of binding sites and efficacy of a species-specific peptide at rat and human neurotensin receptors. J. Pept. Res. 2000, 55, 72-80.
28. Hertel, P.; Byskov, L.; Didriksen, M.; Arnt, J. Induction of tolerance to the suppressant effect of the neurotensin analogue NT69L on amphetamine-induced hyperactivity. Eur. J. Pharmacol. 2001, 422, 77-81.
29. Tyler-McMahon, B. M.; Stewart, J. A.; Farinas, F.; McCormick, D. J.; Richelson, E. Highly potent neurotensin analogue that causes hypothermia and antinociception. Eur. J. Pharmacol. 2000, 390, 107-111.
30. ω) analogues of arginine. J. Org. Chem. 1999, 64, 9265-9267.
31. Lundquist, J. T. IV.; Dix, T. A. Asymmetric synthesis of ω-bromo2(S)-azido acids as precursors for the synthesis of novel amino acids. Tetrahedron Lett 1998, 39, 775-778.
32. Lundquist, J. T. IV.; Büllesbach, E. E.; Dix, T. A. Synthesis of protected χ-mercapto amino acids: precursors for incorporation of elongated cysteines into peptides. Tetrahedron Asymmetry 1998, 9, 2739-2743.
33. Kennedy, K. J.; Lundquist, J. T. IV.; Simandan, T. L.; Beeson, C. C.; Dix, T. A. Asymmetric synthesis of non-natural homologues of lysine. Bioorg. Med. Chem. Lett. 1997, 14, 1937-1940.
34. Kennedy, K. J.; Simandan, T. L.; Dix, T. A. A facile route to cyclic and acyclic alkyl-arginines. Synth. Commun. 1998, 28, 741-746.
35. Kennedy, K. J.; Lundquist, J. T. IV.; Simandan, T. L.; Kokko, K. P.; Beeson, C. C. et al. Design rationale, synthesis, and characterization of non-natural analogues of the cationic amino acids arginine and lysine. J Pept. Res. 2000, 55, 348-358.
36. Beeson, C. C.; Dix, T. A. Thermodynamic description of a contact and solvent-separated ion pair as a function of solvation: A model for salt bridges and proton-transfer reactions in biology. J. Am. Chem. Soc. 1993, 115, 10275-10281.
37. Kokko, K. P.; Dix, T. A. Monitoring neurotensin[8-13] degradation in human and rat serum utilizing matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal. Biochem. 2002, 308, 34-41.
38. Burton, P. S.; Conradi, R. A.; Ho, N. F.; Hilgers, A. R.; Borchardt, R. T. How structural features influence the biomembrane permeability of peptides. J. Pharm. Sci. 1996, 85, 1336-1340.
39. Lundquist, J. T. IV.; Büllesbach, E. E.; Golden, P. L.; Dix, T. A. Topography of the neurotensin(NT)(8-9) binding site of human NT receptor-1 probed with NT(8-13) analogues. J. Pept. Res. 2001, 59, 55-61.
40. Cusack, B.; McCormick, D. J.; Pang, Y. P.; Souder, T.; Garcia, R. et al. Pharmacological and biochemical profiles of unique neurotensin 8-13 analogues exhibiting species selectivity, stereoselectivity, and superagonism. J. Biol. Chem. 1995, 270, 18359-18366.
41. Lundquist, J. T. I.; Dix, T. A. Synthesis and human neurotensin receptor binding activities of neurotensin(8-13) analogues containing position 8 alpha-azido-N-alkylated derivatives of ornithine, lysine, and homolysine. J Med. Chem. 1999, 42, 4914-4918.
42. Tyler, B. M.; Douglas, C. L.; Fauq, A.; Pang, Y. P.; Stewart, J. A. et al. In vitro binding and CNS effects of novel neurotensin agonists that cross the blood-brain barrier. Neuropharmacology 1999, 38, 1027-1034.
43. Tyler-McMahon, B. M.; Boules, M.; Richelson, E. Neurotensin: peptide for the next millennium. Regul. Pept. 2000, 93, 125-136.
44. Dal Farra, C.; Sarret, P.; Navarro, V.; Botto, J. M.; Mazella, J. et al. Involvement of the neurotensin receptor subtype NTR3 in the growth effect of neurotensin on cancer cell lines. Int. J. Cancer 2001, 92, 503-509.
45. Camargo, A. C.; Caldo, H.; Emson, P. C. Degradation of neurotensin by rabbit brain endo-oligopeptidase A and endo-oligopeptidase B (proline-endopeptidase). Biochem. Biophys. Res. Commun. 1983, 116, 1151-1159.
46. Cochrane, D. E.; Carraway, R. E.; Boucher, W.; Feldberg, R. S. Rapid degradation of neurotensin by stimulated rat mast cells. Peptides 1991, 12, 1187-1194.
47. Emson, P. C.; Checler, F.; Camargo, A. C.; Pittaway, K.; Williams, B. et al. Neurotensin degradation by soluble and membrane-associated enzymes from the brain. Biochem. Soc. Trans. 1985, 13, 53-54.
48. McDermott, J. R.; Smith, A. I.; Edwardson, J. A.; Griffiths, E. C. Mechanism of neurotensin degradation by rat brain peptidases. Regul. Pept. 1982, 3, 397-404.
49. McDermott, J. R.; Smith, A. I.; Dodd, P. R.; Hardy, J. A.; Edwardson, J. A. Mechanism of degradation of LH-RH and neurotensin by synaptosomal peptidases. Peptides 1983, 4, 25-30.
50. Mentlein, R.; Dahms, P. Endopeptidases 24.16 and 24.15 are responsible for the degradation of somatostatin, neurotensin, and other neuropeptides by cultivated rat cortical astrocytes. J. Neurochem. 1994, 62, 27-36.
51. Sadoul, J. L.; Mazella, J.; Amar, S.; Kitabgi, P.; Vincent, J. P. Preparation of neurotensin selectively iodinated on the tyrosine 3 residue. Biological activity and binding properties on mammalian neurotensin receptors. Biochem. Biophys. Res. Commun. 1984, 120, 812-819.
52. Lundquist, J. T. IV.; Pelletier, J. C. Improved solid-phase peptide synthesis method utilizing alpha-azide-protected amino acids. Org Lett 2001, 3, 781-783.
53. Cullen, B. R. Use of eukaryotic expression technology in the functional analysis of cloned genes. Methods Enzymol. 1987, 152, 684-704.
54. Chabry, J.; Labbe-Jullie, C.; Gully, D.; Kitabgi, P.; Vincent, J. P. et al. Stable expression of the cloned rat brain neurotensin receptor into fibroblasts: binding properties, photoaffinity labeling, transduction mechanisms, and internalization. J. Neurochem. 1994, 63, 19-27.
55. Van Renterghem, C.; Vigne, P.; Barhanin, J.; Schmid-Alliana, A.; Frelin, C. et al. Molecular mechanism of action of the vasoconstrictor peptide endothelin. Biochem. Biophys. Res. Commun. 1988, 157, 977-985.